Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 65 of 228 for:    yeast

Safety and Pharmacokinetics of Phaffia Rhodozyma Astaxanthin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03807050
Recruitment Status : Completed
First Posted : January 16, 2019
Last Update Posted : March 21, 2019
Sponsor:
Information provided by (Responsible Party):
NextFerm Technologies LTD

Brief Summary:

Astaxanthin is a xanthophyll carotenoid, a naturally occurring lipid-soluble red pigment. Apart from its coloring ability it is also a strong antioxidative ingredient and contains health-promoting properties.

Study aim is to monitor the safety and tolerability of AstaFerm™, an astaxanthin dietary supplement derived from the yeast Phaffia rhodozyma. Pharmacokinetics profile is tested in 12 healthy male adults who received a single dose of AstaFerm™ in a single-center, open-label, non-randomized, single-dose study. Subjects are admitted to the clinical research center on the evening before dosing. On the next morning, after overnight fast, pre-dosing plasma sampling is performed, then they receive a fat balanced breakfast followed by a single administration of AstaFerm™ capsules. The capsules contain 50 milligram astaxanthin derived from Phaffia rhodozyma. Following dosing, blood sampling is performed for 24 hours in-house (2, 4, 6, 8, 10, 12 and 24-hours post-dose) and ambulatory at 48, 72- and 168-hours post-dose. Blood for antioxidant activity assessment is also drawn.


Condition or disease Intervention/treatment Phase
Absorption; Chemicals Dietary Supplement: Astaxanthin Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Safety and Pharmacokinetics of Astaxanthin-Rich Carotenoid Extract (AstaFerm™) Administered as a Single Oral Dose to Healthy Adults
Actual Study Start Date : November 19, 2018
Actual Primary Completion Date : December 23, 2018
Actual Study Completion Date : February 1, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Astaxanthin

Arm Intervention/treatment
Experimental: Astaxanthin
Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
Dietary Supplement: Astaxanthin
Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
Other Name: AstaFerm




Primary Outcome Measures :
  1. Cmax [ Time Frame: Estimated to be at 8 to 10 hours after dosing ]
    The maximum plasma concentration obtained in average of 12 subjects

  2. AUC 0-t [ Time Frame: 168 hours after dosing ]
    Calculate Area under the plasma concentration versus time curve from time =0 h to time of the last measurable concentration of 12 subjects

  3. Time max [ Time Frame: Estimated to be at 8 to 10 hours after dosing ]
    Time at which Cmax occurs


Secondary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: 15 days ]
    Number of subjects that reported incidence of adverse events and details of adverse events that were reported



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 46 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male volunteers between 18 and <46 years of age.
  2. Subjects who provide written informed consent to participate in the study.
  3. BMI ranging from 18.0 to <30.0, calculated as Weight (Kg)/Height (m2).
  4. Non-smoking (by declaration) for a period of at least 6 months.
  5. No known history of significant neurological, renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrine, gastrointestinal, hepatic or hematopoietic disease, neoplasm, psychiatric or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications.
  6. No history of drug or alcohol abuse.
  7. No known allergy or hypersensitivity to any drug or food.
  8. No clinically significant abnormalities in screening physical exam.
  9. No clinically significant abnormalities in clinical laboratory parameters (hematology, biochemistry and urinalysis) at Screening, as determined by the study physicians.
  10. Negative HIV antibody, Hepatitis B surface antigen and Hepatitis C antibody tests at Screening.
  11. No significant abnormalities in electrocardiogram.at Screening.
  12. Subjects with negative urinary drugs of abuse screen determined at Screening and on admission to the clinical research center prior to dosing day.
  13. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  14. Subjects must satisfy a medical examiner about their fitness to participate in the study.

Exclusion Criteria:

  1. Subjects with any clinically significant abnormality upon physical examination or in the clinical laboratory test values.
  2. Subjects with a history of clinically defined peptic ulcer or any gastrointestinal surgery other than appendectomy or herniotomy, or with any gastrointestinal disorder likely to influence supplement absorption, or with any history of severe gastrointestinal narrowing, or frequent nausea or emesis, regardless of etiology.
  3. Subjects with significant allergic response to any drug or history of food allergies deemed clinically significant or exclusionary for the study.
  4. Adherence (for whatever reason) to an abnormal diet during the 4 weeks prior to the study, or subjects with recent significant change in body weight.
  5. Treatment with prescription or over-the-counter drugs, nutraceuticals including vitamins, herbal medications, food supplements and other prescription drugs not mentioned above, within 7 days prior to first dosing day.
  6. Use of paracetamol (acetaminophen) less than 24 hours before the first dosing day.
  7. Subjects who donated blood or received blood or plasma derivatives in the three months preceding the first study dosing.
  8. Participation in another clinical trial with drugs within 3 months prior to first study dosing day (calculated from the previous study's last dosing date).
  9. Subjects with an inability to communicate well with the investigators and Clinical research Center staff (i.e., language problem, poor mental development or impaired cerebral function).
  10. Subjects that have difficulty fasting or consuming the standard meals that will be provided.
  11. Subjects with any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.
  12. Subjects who are non-cooperative or unwilling to sign the consent form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03807050


Locations
Layout table for location information
Israel
Sourasky Medical Center
Tel-Aviv, Israel, 6423906
Sponsors and Collaborators
NextFerm Technologies LTD
Investigators
Layout table for investigator information
Principal Investigator: Oren Shibolet, Prof. Tel Aviv Sourasky Medical Center Israel

Layout table for additonal information
Responsible Party: NextFerm Technologies LTD
ClinicalTrials.gov Identifier: NCT03807050     History of Changes
Other Study ID Numbers: AstaFerm 001
First Posted: January 16, 2019    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NextFerm Technologies LTD:
Pharmacokinetics